Company: XOMAP
Filing Date: 2025-08-04
Form Type: SC TO-C
Source: 0001193125-25-172163
Chunk: 2

Company: XOMA Royalty Corp
Filing Date: 2025-08-04
Form: SC TO-C
Chunk 2
---
 outcome of any legal proceedings that have been or could be instituted against the Buyer Entities, HilleVax or their respective directors; the risk that the
transactions may not be completed in a timely manner, or at all, which may adversely affect HilleVax’s or Parent’s respective businesses and the price of their respective common stock; the failure to satisfy all of the closing conditions
of the transactions contemplated by the Merger Agreement; the occurrence of the events giving rise to payments under the Contingent Value Rights (“”) Agreement; the occurrence of any event, change or other circumstance that could
give rise to the termination of the Merger Agreement; the effect of the announcement or pendency of the transactions on HilleVax’s and Parent’s respective businesses and operating results; risks that the transactions may disrupt
HilleVax’s or Parent’s respective current plans and business operations; risks related to the diverting of management’s attention from HilleVax’s and Parent’s respective ongoing business operations; general economic and
market conditions and the other risks identified in HilleVax’s and Parent’s respective filings with the SEC and subsequent filings with the SEC. Should any risks and uncertainties develop into actual events, these developments could have a
material adverse effect on the transactions and/or HilleVax and the Buyer Entities’ ability to successfully complete the transactions and, with respect to any CVR payment amounts, the consideration ultimately paid to HilleVax stockholders
(including whether any payments will be payable at all). In addition, unlisted factors may present significant additional obstacles to the realization of forward-looking statements. The Buyer Entities caution investors not to place undue reliance on
any forward-looking statements. Any forward-looking statements contained in this communication represent the Buyer Entities’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The
Buyer Entities disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the forward-looking statements.

Additional Information and Where to Find It The tender offer for the Shares of HilleVax referenced in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that the Buyer Entities will file with